Metagenomi Therapeutics Price to Book Ratio 2022-2026 | MGX

Historical price to book ratio values for Metagenomi Therapeutics (MGX) over the last 10 years. The current price to book ratio for Metagenomi Therapeutics as of September 17, 2026 is 0.38.

Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Metagenomi Therapeutics Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2026-09-17 1.13 0.38
2026-06-30 1.19 $2.98 0.40
2026-03-31 1.34 $3.66 0.37
2025-12-31 1.62 $4.22 0.38
2025-09-30 2.37 $4.75 0.50
2025-06-30 1.48 $5.22 0.28
2025-03-31 1.36 $5.69 0.24
2024-12-31 3.61 $6.28 0.58
2024-09-30 2.17 $6.83 0.32
2024-06-30 4.08 $7.19 0.57
2024-03-31 10.55 $7.36 1.43
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.043B $0.025B
Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $44.899B 17.67
BridgeBio Pharma (BBIO) United States $13.352B 0.00
Dr Reddy's Laboratories (RDY) India $9.749B 24.85
Aspen Pharmacare (APNHY) South Africa $4.248B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.409B 20.18
Bausch Health Cos (BHC) Canada $2.129B 1.33
Personalis (PSNL) United States $1.687B 0.00
Taysha Gene Therapies (TSHA) United States $1.652B 0.00
Amphastar Pharmaceuticals (AMPH) United States $1.019B 9.58
Assembly Biosciences (ASMB) United States $0.519B 24.98
Sol-Gel Technologies (SLGL) Israel $0.178B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00